新西兰制药公司报告说,2024年取得了成功,计划在2025年对肥胖药物进行三次新的试验。 Zealand Pharma reports successful 2024, plans three new trials for obesity drugs in 2025.

新西兰制药公司是一家专注于肥胖症治疗的生物技术公司,它报告说,2024年取得了成功,其药物候选者,包括石丁酸和沙丁酸,都取得了积极的临床试验结果。 Zealand Pharma, a biotech firm focusing on obesity treatments, reported a successful 2024 with positive clinical trial results for its drug candidates, including petrelintide and dapiglutide. 该公司筹集了12亿美元,促进了研发投资。 The company raised $1.2 billion, enabling R&D investments. 2025年,新西兰计划启动三个阶段的2b试验,目的是进一步推动肥胖症治疗。 In 2025, Zealand plans to launch three Phase 2b trials, aiming for further advancements in obesity treatments.